FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.
What happened
FDA inspected the facility from March 18 to 22, 2024. Investigators said the company limited the inspection by providing redacted records, allowing only part of a CAPA list, refusing photos of dirty filling machines, and denying access to a manufacturing room. FDA also observed residues on filling machines marked clean, equipment in disrepair, and gaps in process validation and stability testing.
What FDA found
FDA says the company limited and refused inspection by redacting records, allowing only part of a CAPA list, refusing photos, and denying access to a manufacturing room.
section 501(j) of the FD&C Act, 21 U.S.C. 351(j)FDA observed residues on filling machines marked clean and equipment in disrepair, including missing screws and broken parts.
21 CFR 211.67(a)The company did not provide data showing its OTC drug manufacturing process was validated and reproducible.
21 CFR 211.100(a)The analytical method was not stability-indicating and forced degradation studies were not done.
21 CFR 211.160(a) and 21 CFR 211.166
What FDA wants
FDA asks the company to correct the violations promptly and respond in writing within 15 working days with CAPA plans, unredacted records, and assessments of cleaning, validation, and stability. FDA says it may withhold approvals and refuse U.S. imports until compliance is confirmed.
Who should pay attention
- U.S. drug importers and distributors sourcing from this firm
- brands using this contract manufacturer for OTC topical drugs
- quality teams managing supplier qualification and CGMP audits in China
This is a summary. Read the original letter on fda.gov.